Novavax Announces Favorable Interim Results From Human Clinical Trial For Its Pandemic Influenza Vaccine Program

Novavax, Inc.(Nasdaq: NVAX) announced favorable interim results from a Phase I/IIa human clinical trial of its non-adjuvanted pandemic influenza virus-like particle (VLP) vaccine candidate. Penny Heaton, MD, Chief Medical Officer and Head of Clinical Development stated, “The initial results from our Phase I/IIa study are promising and support further development of our pandemic influenza vaccine through regulatory licensure. [click link for full article]

More: continued here

Filed under: Bird Flu on December 24th, 2007